The earnings call reflects a strong financial performance and strategic progress, particularly with PIC's growth and the VAP initiatives. However, ABS faces challenges in China and Brazil, and currency headwinds are impacting profitability. R&D spend has decreased, but the company remains committed to innovation. Overall, the positive aspects outweigh the negatives.

Company Guidance

In the call, Genus provided comprehensive guidance highlighting several key metrics. PIC, excluding China, achieved a notable 13% increase in operating profit for the first half of the fiscal year 2025. Despite challenges in China, Genus signed seven new royalty customers, establishing contracts with three of the top five producers in the largest porcine market globally. The company's Value Acceleration Program (VAP) is on track to deliver a GBP 21 million annual run rate benefit by the end of the fiscal year, with notable improvements in cash flow due to better inventory management. Adjusted operating profit saw a 19% growth, reaching GBP 45.2 million, and adjusted profit before tax increased by 21% to GBP 35.4 million. The interim dividend was maintained at 10.3p per share. Additionally, the company expects FDA approval for its PRRS Resistant Pig (PRP) in calendar year 2025, with ongoing regulatory engagements in other international markets showing promise. Despite foreign exchange headwinds, Genus reaffirmed its fiscal year 2025 profit before tax (PBT) guidance, anticipating significant growth in PBT in actual currency.

Strong Financial Performance in H1 FY25

Adjusted operating profit grew 19% to GBP 45.2 million, and adjusted profit before tax grew 21% to GBP 35.4 million. This was a record first-half performance.

PIC's Impressive Growth

PIC achieved a 13% increase in operating profit excluding China, and a 9% volume increase overall. Latin America showed standout growth with a 13% operating profit increase in constant currency.

Value Acceleration Program (VAP) Success

VAP initiatives have delivered significant benefits, with GBP 6.3 million achieved in the first half, and an expected GBP 21 million run rate benefit by the end of the fiscal year.

Progress in PRP Commercialization

Significant progress with the FDA for PRP approval, with site inspections conducted and expected approval in 2025, marking a major opportunity from Genus's R&D program.

Improved Cash Flow and Debt Management

Return to positive free cash flow with improved working capital and inventory management, and a net debt to EBITDA ratio of 2x, within the target range.

Genus plc (GB:GNS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:GNS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 19, 2026	2026 (Q2)	- / -	0.394	―	―	―
Sep 04, 2025	2025 (Q4)	- / 0.27	-0.085	415.29% (+0.35)	―	―
Feb 27, 2025	2025 (Q2)	- / 0.39	0.331	19.03% (+0.06)	―	―
Sep 05, 2024	2024 (Q4)	- / -0.09	0.304	-127.96% (-0.39)	―	―
Feb 22, 2024	2024 (Q2)	0.33 / 0.33	0.485	-31.75% (-0.15)	―	―
Sep 07, 2023	2023 (Q4)	- / 0.30	0.321	-5.30% (-0.02)	―	―
Feb 23, 2023	2023 (Q2)	- / 0.48	0.421	15.20% (+0.06)	―	―
Sep 08, 2022	2022 (Q4)	- / 0.32	0.242	32.64% (+0.08)	―	―
Feb 24, 2022	2022 (Q2)	- / 0.42	0.569	-26.01% (-0.15)	―	―
Sep 09, 2021	2021 (Q4)	- / 0.24	0.259	-6.56% (-0.02)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:GNS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Sep 04, 2025	2500.00p	2760.00p	+10.40%
Feb 27, 2025	1820.03p	1740.46p	-4.37%
Sep 05, 2024	1764.45p	1717.24p	-2.68%
Feb 22, 2024	1869.92p	1922.73p	+2.82%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Genus PLC (GB:GNS) report earnings?

Genus PLC (GB:GNS) is schdueled to report earning on Feb 19, 2026, TBA (Confirmed).

What is Genus PLC (GB:GNS) earnings time?

Genus PLC (GB:GNS) earnings time is at Feb 19, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Genus PLC stock?

The P/E ratio of Genus plc is N/A.

What is GB:GNS EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing